View in EDS

Development of a Series of Pyrrolopyridone MAT2A Inhibitors.

Saved in:
Bibliographic Details
Title: Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
Authors: Atkinson SJ; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Bagal SK; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Argyrou A; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Askin S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Cheung T; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Chiarparin E; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Coen M; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Collie IT; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Dale IL; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., De Fusco C; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Dillman K; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Evans L; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Feron LJ; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Foster AJ; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Grondine M; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Kantae V; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lamont S; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lynch JT; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Nilsson Lill S; Data Sciences & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 431 83, Sweden., Robb GR; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Saeh J; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Schimpl M; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Scott JS; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Smith J; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Srinivasan B; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Tentarelli S; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Vazquez-Chantada M; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Wagner D; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Walsh JJ; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Watson D; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Williamson B; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.
Source: Journal of medicinal chemistry [J Med Chem] 2024 Mar 28; Vol. 67 (6), pp. 4541-4559. Date of Electronic Publication: 2024 Mar 11.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38466661
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Atkinson+SJ%22">Atkinson SJ</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Bagal+SK%22">Bagal SK</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Argyrou+A%22">Argyrou A</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Askin+S%22">Askin S</searchLink>; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Cheung+T%22">Cheung T</searchLink>; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Chiarparin+E%22">Chiarparin E</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Coen+M%22">Coen M</searchLink>; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Collie+IT%22">Collie IT</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Dale+IL%22">Dale IL</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22De+Fusco+C%22">De Fusco C</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Dillman+K%22">Dillman K</searchLink>; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Evans+L%22">Evans L</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Feron+LJ%22">Feron LJ</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Foster+AJ%22">Foster AJ</searchLink>; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Grondine+M%22">Grondine M</searchLink>; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Kantae+V%22">Kantae V</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Lamont+GM%22">Lamont GM</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Lamont+S%22">Lamont S</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Lynch+JT%22">Lynch JT</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Nilsson+Lill+S%22">Nilsson Lill S</searchLink>; Data Sciences & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 431 83, Sweden.<br /><searchLink fieldCode="AU" term="%22Robb+GR%22">Robb GR</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Saeh+J%22">Saeh J</searchLink>; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Schimpl+M%22">Schimpl M</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Scott+JS%22">Scott JS</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Smith+J%22">Smith J</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Srinivasan+B%22">Srinivasan B</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Tentarelli+S%22">Tentarelli S</searchLink>; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Vazquez-Chantada+M%22">Vazquez-Chantada M</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Wagner+D%22">Wagner D</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Walsh+JJ%22">Walsh JJ</searchLink>; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Watson+D%22">Watson D</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Williamson+B%22">Williamson B</searchLink>; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229716531%22">Journal of medicinal chemistry</searchLink> [J Med Chem] 2024 Mar 28; Vol. 67 (6), pp. 4541-4559. <i>Date of Electronic Publication: </i>2024 Mar 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Chemical+Society%22">American Chemical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9716531 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1520-4804 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200222623%22">00222623 </searchLink><i>NLM ISO Abbreviation: </i>J Med Chem <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38466661
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1021/acs.jmedchem.3c01860
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4541
    Titles:
      – TitleFull: Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Atkinson SJ
      – PersonEntity:
          Name:
            NameFull: Bagal SK
      – PersonEntity:
          Name:
            NameFull: Argyrou A
      – PersonEntity:
          Name:
            NameFull: Askin S
      – PersonEntity:
          Name:
            NameFull: Cheung T
      – PersonEntity:
          Name:
            NameFull: Chiarparin E
      – PersonEntity:
          Name:
            NameFull: Coen M
      – PersonEntity:
          Name:
            NameFull: Collie IT
      – PersonEntity:
          Name:
            NameFull: Dale IL
      – PersonEntity:
          Name:
            NameFull: De Fusco C
      – PersonEntity:
          Name:
            NameFull: Dillman K
      – PersonEntity:
          Name:
            NameFull: Evans L
      – PersonEntity:
          Name:
            NameFull: Feron LJ
      – PersonEntity:
          Name:
            NameFull: Foster AJ
      – PersonEntity:
          Name:
            NameFull: Grondine M
      – PersonEntity:
          Name:
            NameFull: Kantae V
      – PersonEntity:
          Name:
            NameFull: Lamont GM
      – PersonEntity:
          Name:
            NameFull: Lamont S
      – PersonEntity:
          Name:
            NameFull: Lynch JT
      – PersonEntity:
          Name:
            NameFull: Nilsson Lill S
      – PersonEntity:
          Name:
            NameFull: Robb GR
      – PersonEntity:
          Name:
            NameFull: Saeh J
      – PersonEntity:
          Name:
            NameFull: Schimpl M
      – PersonEntity:
          Name:
            NameFull: Scott JS
      – PersonEntity:
          Name:
            NameFull: Smith J
      – PersonEntity:
          Name:
            NameFull: Srinivasan B
      – PersonEntity:
          Name:
            NameFull: Tentarelli S
      – PersonEntity:
          Name:
            NameFull: Vazquez-Chantada M
      – PersonEntity:
          Name:
            NameFull: Wagner D
      – PersonEntity:
          Name:
            NameFull: Walsh JJ
      – PersonEntity:
          Name:
            NameFull: Watson D
      – PersonEntity:
          Name:
            NameFull: Williamson B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 03
              Text: 2024 Mar 28
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1520-4804
          Numbering:
            – Type: volume
              Value: 67
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Journal of medicinal chemistry
              Type: main
ResultId 1